PROVIDER*Update*

CONTRACTUAL | FEBRUARY 14, 2024 | UPDATE 24-185 | 2 PAGES

View the New Web Page for Medicare Medical Policies

Added clinical policies and updated Concert Genetics policies to the new web page

The medical policies listed in this update were approved by Centene's National Medicare Quality Improvement Utilization Management Committee and are effective as of January 1, 2024. For a complete description of the background, criteria, references, and coding implications for these Medicare medical policies, go to bit.ly/WC_ClinicalGuidelines.

Apply the Medicare National Coverage Decisions (NCDs) and applicable Local Coverage Decisions (LCDs) local policies for primary coverage guidance.

Updated clinical policies effective January 1

The following Medicare Clinical Policies contain changes to their previous versions and have been approved for use. The listed policies are in numeric order and are effective as of January 1, 2024.

- MC.CP.MP.22 Stereotactic Body Radiation Therapy
- MC.CP.MP.57 Lung Transplantation
- MC.CP.MP.69 Intensity-Modulated Radiotherapy
- MC.CP.MP.101 Donor Lymphocyte Infusion
- MC.CP.MP.106 Endometrial Ablation
- MC.CP.MP.108 Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and Beta-thalassemia
- MC.CP.MP.160 Wireless Pulmonary Artery Monitoring
- MC.CP.MP.170 Peripheral Nerve Blocks
- MC.CP.MP.182 Short Inpatient Stay
- CP.PP.206 Skilled Nursing Facility Leveling
- MC.CP.MP.246 Pediatric Kidney Transplantation



THIS UPDATE APPLIES TO:

- Physicians
- Hospitals
- Ancillary Providers
- Independent Practice Associations

PROVIDER SERVICES

866-999-3945

PROVIDER PORTAL

provider.wellcare.com/california

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less. The following Concert Genetic Testing policies apply to Medicare:

Concert Genetics – Genetic Testing

Policy Name	Policy Name	Policy Name
Algorithmic Testing	Aortopathies and Connective Tissue Disorders	Cancer Screening
Cardiac Disorders	Dermatologic Conditions	Epilepsy, Neurodegenerative, and Neuromuscular Disorders
Exome and Genome Sequencing for the Diagnosis of Genetic Disorders	Eye Disorders	Gastroenterologic Disorders (Non- Cancerous)
General Approach to Genetic and Molecular Testing	Hearing Loss	Hematologic Conditions (Non- Cancerous)
Hereditary Cancer Susceptibility	Immune, Autoimmune, and Rheumatoid Disorders	Kidney Disorders
Lung Disorders	Metabolic, Endocrine, and Mitochondrial Disorders	Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay
Non-Invasive Prenatal Screening (NIPS)	Pharmacogenetics	Preimplantation Genetic Testing
Prenatal and Preconception Carrier Screening	Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss	Skeletal Dysplasia and Rare Bone Disorders

Concert Genetics – Oncology

Policy Name	Policy Name	Policy Name
Cytogenetic Testing	Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy)	Molecular Analysis of Solid Tumors and Hematologic Malignancies

Additional information

If you have questions regarding the information contained in this update, contact 866-999-3945.